235 related articles for article (PubMed ID: 33737682)
1. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Notsu A
Sci Rep; 2021 Mar; 11(1):6328. PubMed ID: 33737682
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
3. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer.
Masuda T; Ueo H; Okumura Y; Kai Y; Ando Y; Masuguchi K; Kitagawa M; Kitagawa A; Hayashi N; Tsuruda Y; Hisamatsu Y; Suehiro S; Ohmura H; Fujiyoshi K; Tanaka F; Mimori K
Cancer Genomics Proteomics; 2023; 20(2):182-194. PubMed ID: 36870689
[TBL] [Abstract][Full Text] [Related]
5. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
Watanabe J; Saito M; Horimoto Y; Nakamoto S
Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
[TBL] [Abstract][Full Text] [Related]
6. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
7. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
8. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients.
Losada B; Guerra JA; Malón D; Jara C; Rodriguez L; Del Barco S
Clin Transl Oncol; 2019 Jul; 21(7):855-863. PubMed ID: 30506134
[TBL] [Abstract][Full Text] [Related]
10. Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis.
Tham T; Wotman M; Chung C; Ahn S; Dupuis H; Gliagias V; Movsesova T; Kraus D; Costantino P
Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2913-2922. PubMed ID: 31312922
[TBL] [Abstract][Full Text] [Related]
11. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
12. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.
Zhang GM; Zhu Y; Luo L; Wan FN; Zhu YP; Sun LJ; Ye DW
Tumour Biol; 2015 Nov; 36(11):8537-43. PubMed ID: 26032095
[TBL] [Abstract][Full Text] [Related]
13. The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Kuwahara C
Cancer Diagn Progn; 2021; 1(5):471-478. PubMed ID: 35403159
[TBL] [Abstract][Full Text] [Related]
14. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
15. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients.
Eren T; Karacin C; Ucar G; Ergun Y; Yazici O; İmamoglu Gİ; Ozdemir N
Medicine (Baltimore); 2020 May; 99(22):e20346. PubMed ID: 32481414
[TBL] [Abstract][Full Text] [Related]
16. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
Lee KH; Kim EY; Yun JS; Park YL; Do SI; Chae SW; Park CH
BMC Cancer; 2018 Oct; 18(1):938. PubMed ID: 30285668
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma.
Yapar A; Tokgöz MA; Yapar D; Atalay İB; Ulucaköy C; Güngör BŞ
Jt Dis Relat Surg; 2021; 32(2):489-496. PubMed ID: 34145828
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
[TBL] [Abstract][Full Text] [Related]
20. Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.
Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
Sci Rep; 2021 Nov; 11(1):21454. PubMed ID: 34728668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
